Should adjuvant weekly paclitaxel be considered less efficacious than anthracyclines plus cyclophosphamide for lower-risk patients with early-stage breast cancer?

Affiliations

¹ University of Brescia at Spedali Civili Hospital, Brescia, Italy vitoamoroso@alice.it.
² Spedali Civili Hospital, Brescia, Italy.
³ Barts and The London School of Medicine and Dentistry, London, United Kingdom.
⁴ University of Brescia at Spedali Civili Hospital, Brescia, Italy.
⁵ University of Brescia, Brescia, Italy.

Comment

Vito Amoroso et al. J Clin Oncol. 2015.

. 2015 Jan 20;33(3):290.

doi: 10.1200/JCO.2014.58.7923. Epub 2014 Dec 15.

¹ University of Brescia at Spedali Civili Hospital, Brescia, Italy vitoamoroso@alice.it.
² Spedali Civili Hospital, Brescia, Italy.
³ Barts and The London School of Medicine and Dentistry, London, United Kingdom.
⁴ University of Brescia at Spedali Civili Hospital, Brescia, Italy.
⁵ University of Brescia, Brescia, Italy.

No abstract available

Comment in

Reply to V. Amoroso et al.
Shulman LN, Berry DA, Cirrincione CT, Hudis CA, Winer EP. Shulman LN, et al. J Clin Oncol. 2015 Jan 20;33(3):291. doi: 10.1200/JCO.2014.59.1875. Epub 2014 Dec 15. J Clin Oncol. 2015. PMID: 25512457 No abstract available.

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Shulman LN, et al. J Clin Oncol. 2014 Aug 1;32(22):2311-7. doi: 10.1200/JCO.2013.53.7142. Epub 2014 Jun 16. J Clin Oncol. 2014. PMID: 24934787 Free PMC article. Clinical Trial.